ライフサイエンスコーパス: growth hormone

1 sometimes associated with hypersecretion of growth hormone.

2 ed Down syndrome, vitamin A derivatives, and growth hormone.

3 t be rescued by administration of ghrelin or growth hormone.

4 UAG, reduced DI and kg and increased plasma growth hormone.

5 -onset gigantism resulting from an excess of growth hormone.

6 s for the mammatrophic hormones estrogen and growth hormone.

7 he removal of the counter-insulin effects of growth hormone.

8 mediates the growth-promoting activities of growth hormone.

9 being nuclear RNA enriched and regulated by growth hormone.

10 tion of oleic acid and the overproduction of growth hormone.

11 position, which may affect the regulation of growth hormones.

12 and IL-22, and hormonal modulation including growth hormone administration and sex steroid inhibition

13 ulation including sex steroid inhibition and growth hormone administration.

14 b, letrozole, Y-27632, octreotide, and human growth hormone, all delivered at clinically-relevant dos

15 The sensing of bovine growth hormone also known as bovine somatotropin (bST) s

16 Of these patients, 8374 of received growth hormone and 1267 did not.

17 enes interact with NFkbeta, ERK, MAPK, VEGF, growth hormone and collagen to produce a network whose t

18 n promotes gastric emptying and secretion of growth hormone and inhibits inflammation.

19 Unique sequence changes in growth hormone and insulin-like growth factor 1 receptor

20 d without increases in circulating levels of growth hormone and insulin-like growth factor I and were

21 at GH3 cells, it led to increased release of growth hormone and proliferation of growth hormone-produ

22 gly, this period of growth is independent of growth hormone and the underlying mechanism is poorly un

23 od for the bacteria and the bacteria produce growth hormones and antibiotics for the algae, or parasi

24 red in the presence or the absence of IGF-1, growth hormone, and an IGF-1 receptor-blocking antibody.

25 nd prolactin deficiencies, whereas for ACTH, growth hormone, and antidiuretic hormone deficiency dyna

26 of thyroxine, hydrocortisone, sex steroids, growth hormone, and desmopressin.

27 Levels of insulin, cortisol, growth hormone, and noradrenaline, as well as hypoglycem

28 ma concentrations of 25 different cytokines, growth hormones, and other factors which have previously

29 Treatment with growth hormone appears safe in the short term, while dat

30 ion, or lipid accumulation in these cells by growth hormone application.

31 With the use of human growth hormone as a model protein, the potential of ion

32 -microglobulin, immunoglobulin G1, and human growth hormone as model systems, we demonstrate that DEP

33 of ghrelin, which includes the secretion of growth hormone, as well as the stimulation of appetite,

34 Indeed, short-term treatment with growth hormone augmented senescent host liver repopulati

35 leads to the formation of a gradient of the growth hormone auxin across the photo-stimulated stem.

36 In plants, the growth hormone auxin induces stem elongation in response

37 e directional, cell-to-cell transport of the growth hormone auxin to generate an asymmetric auxin res

38 ating glucose, altered lipid metabolism, and growth hormone axis perturbations, can promote senescent

39 ich may relate to contamination of different growth hormone batches with different strains of human p

40 onstrated functional complexation with human growth hormone binding protein (hGHBp) to the different

41 bances (leptin, afamin), stunting of growth (growth hormone binding protein), and connective tissue r

42 lant, early institution of recombinant human growth hormone can promote growth.

43 e inadequately controlled (5-point, 2 h mean growth hormone concentration >2.5 mug/L and insulin-like

44 hieving biochemical control, defined as mean growth hormone concentration less than 2.5 mug/L and nor

45 ous treatment (octreotide or lanreotide) and growth hormone concentrations at screening (2.5-10 mug/L

46 tion in childhood has been related to higher growth-hormone concentrations that may affect mammary gl

47 hood, with human cadaveric pituitary-derived growth hormone contaminated with prions.

48 ns of epinephrine, norepinephrine, glucagon, growth hormone, cortisol, endogenous glucose production,

49 UAG did not alter growth hormone, cortisol, glucagon, or free fatty acid l

50 Individual growth hormone deficiencies can develop after a dose as

51 The most common endocrine disorders were growth hormone deficiency (12.5%), precocious puberty (1

52 Growth hormone deficiency (GHD) after TBI may impair axo

53 yroid cancer (HR, 9.2; 95% CI, 6.2 to 13.7), growth hormone deficiency (HR, 5.3; 95% CI, 4.3 to 6.4),

54 ildren (mean 8.8 years of age) with isolated growth hormone deficiency [peak growth hormone <6.7 micr

55 h whole-genome resequencing in patients with growth hormone deficiency and maternally inherited gingi

56 crinology clinic where he was diagnosed with growth hormone deficiency and was started on replacement

57 he regulation of human growth, and show that growth hormone deficiency associated with maternally inh

58 Pituitary hormone deficiencies, with Growth Hormone deficiency being most frequent (1 in 3,50

59 ment on fracture risk in adult patients with growth hormone deficiency exist.

60 treatment on fracture risk in patients with growth hormone deficiency from the international Hypopit

61 opy were significantly lower in the isolated growth hormone deficiency group.

62 mpared with controls, children with isolated growth hormone deficiency had lower Full-Scale IQ (P < 0

63 e treatment are now required to confirm that growth hormone deficiency impacts significantly on brain

64 Familial growth hormone deficiency provides an opportunity to ide

65 ocus, in a large family in which an isolated growth hormone deficiency segregates as an autosomal dom

66 this prospective cohort study, patients with growth hormone deficiency were analysed from the HypoCCS

67 ive against fracture for adult patients with growth hormone deficiency without previously reported os

68 with adrenocorticotropic hormone deficiency, growth hormone deficiency, and mild ectodermal dysplasia

69 We identified growth hormone deficiency, central diabetes insipidus, a

70 to valvular aortic stenosis, acromegaly, or growth hormone deficiency, conditions associated with al

71 or older and had an established diagnosis of growth hormone deficiency, either alone or with multiple

72 se progressed, including diabetes insipidus, growth hormone deficiency, primary hypogonadism, adrenal

73 syndrome, coeliac disease, cystic fibrosis, growth hormone deficiency, renal tubular acidosis, and s

74 timum for bone health of adult patients with growth hormone deficiency.

75 hthalmia, hypogonadotrophic hypogonadism and growth hormone deficiency.

76 0.02) standard deviation scores in isolated growth hormone deficiency.

77 ynthesis and secretion of VLDL-TAG using the growth hormone-deficient Ames dwarf mouse model, which h

78 icit at 5 years was 55% (95% CI 41-67), with growth hormone deficit being most common.

79 up method, for the characterization of human growth hormone degradation products.

80 rns with muscularity and use of supplements, growth hormone derivatives, or anabolic steroids to achi

81 t source of infecting prion contamination of growth hormone derived from a patient with Creutzfeldt-J

82 In addition, growth hormone displayed a delayed response but to a hig

83 ase due to administration of cadaver-sourced growth hormone during childhood are still being seen in

84 erentiated further into cholangiocytes using growth hormone, epidermal growth factor, interleukin-6,

85 xposure of young and old HSCs to recombinant growth hormone ex vivo led to diminished short-term reco

86 the hypothalamus and, subsequently, reduced growth hormone expression in the pituitary glands of the

87 e shown previously that the murine prolactin/growth hormone family member proliferin plays a pivotal

88 Accordingly, the administration of dTMP-growth hormone fusion protein led to a rapid platelet re

89 date genes in these two regions included the growth hormone gene (GH1) on SSC12 and PRKD1 on SSC7.

90 alar in food ingredients based on the salmon growth hormone gene 1 (GH1).

91 Life-long lack of growth hormone (GH) action can produce remarkable extens

92 induced in males in the liver and kidney by growth hormone (GH) and androgen, respectively.

93 Plasma growth hormone (GH) and hepatic autophagy each have been

94 he transmembrane domains of the receptors of growth hormone (GH) and insulin-like growth factor 1 (IG

95 During puberty, the serum levels of growth hormone (GH) and its downstream effector IGF-1 in

96 In humans, low levels of growth hormone (GH) and its mediator, IGF-1, associate w

97 finding is the unique expression pattern of growth hormone (Gh) and prolactin (Prl).

98 Both pathological excess and deficiency of growth hormone (GH) are associated with cardiovascular m

99 Levels of growth hormone (GH) are elevated in T1D, which aggravate

100 ats with monosodium glutamate (MSG), a total growth hormone (GH) blocker, and, using cultured hepatoc

101 Persistently high levels of growth hormone (GH) can cause liver cancer.

102 hormone (FSH), luteinizing hormone (LH) and growth hormone (GH) cells.

103 Two soldiers had hyperprolactinemia, 2 had growth hormone (GH) deficiency, 1 had adrenocorticotropi

104 Growth hormone (GH) elicits direct peripheral metabolic

105 Growth hormone (GH) excess in acromegaly is associated w

106 Acromegaly is a human disease of growth hormone (GH) excess with considerable morbidity a

107 somatotroph adenomas result in dysregulated growth hormone (GH) hypersecretion and acromegaly; howev

108 om mice that overexpress or are deficient in growth hormone (GH) indicate that GH stimulates T and B-

109 ssion of FGF21 causes growth attenuation and growth hormone (GH) insensitivity.

110 Growth hormone (GH) is a major metabolic homeostatic fac

111 reduced IGF-I levels without alterations of growth hormone (GH) levels.

112 ver disease (NAFLD) are reported to have low growth hormone (GH) production and/or hepatic GH resista

113 Insulin controls growth hormone (GH) production at multiple levels, inclu

114 Ghrelin is a peptide hormone that stimulates growth hormone (GH) release and positive energy balance

115 Growth hormone (GH) resistance has been associated with

116 ting pituitary somatotroph cells to suppress growth hormone (GH) secretion and treat acromegaly.

117 s is shaped by the male pattern of pituitary growth hormone (GH) secretion that determines body size

118 a close relationship between food intake and growth hormone (GH) secretion; however, the mechanism th

119 Sex-dependent pituitary growth hormone (GH) secretory patterns determine the sex

120 Sex-dependent pituitary growth hormone (GH) secretory profiles-pulsatile in male

121 s have underscored the importance of hepatic growth hormone (GH) signaling in the development of NAFL

122 Growth hormone (GH) signaling is required for promoting

123 Disruption of hepatocyte growth hormone (GH) signaling through disruption of Jak2

124 ytokine signaling 2 (SOCS2), an inhibitor of growth hormone (GH) signaling, was strongly induced afte

125 transcription factor STAT5 in liver impairs growth hormone (GH) signalling and thereby promotes fatt

126 e established genome-wide STAT5 binding upon growth hormone (GH) stimulation of wild-type (WT) mouse

127 expression is transcriptionally regulated by growth hormone (GH) through growth hormone response elem

128 We also examined links between ghrelin and growth hormone (GH), a major downstream effector of the

129 Levels of pituitary growth hormone (GH), a metabolic homeostatic factor with

130 pituitary hormones such as prolactin (PRL), growth hormone (GH), adrenocorticotropic hormone (ACTH),

131 tokine receptors, including leptin, insulin, growth hormone (GH), and nerve growth factor (NGF).

132 ising minimum cortisol and high aldosterone, growth hormone (GH), and prolactin levels, thereby presu

133 ncentration of circulating hormones, such as growth hormone (GH), but the biological functions of thi

134 Growth hormone (GH), prolactin, and insulin are involved

135 Growth hormone-releasing hormone (GHRH) and Growth hormone (GH), underappreciated findings in ARID1B

136 ggest that loss of MC4R function may enhance growth hormone (GH)-mediated growth, although this remai

137 Conversely, inhibition of SHP2 expression in growth hormone (GH)-responsive cell lines results in inc

138 hagic obesity, central hypogonadism, and low growth hormone (GH).

139 ive pituitaries occasionally form aggressive growth-hormone (GH)-producing pituitary tumors in the ba

140 BA; 20 ppm in feed) or Reporcin (recombinant growth hormone; GH; 10 mg/48 hours injected) and compare

141 on, and activity levels) and deficiencies in growth hormone (GHD) and/or sex steroids with low BMD an

142 with cotton DELLA, GhSLR1, repressor of the growth hormone gibberellin (GA).

143 of age) with idiopathic short stature [peak growth hormone >10 microg/l (mean 15 microg/l) and norma

144 Using human growth hormone (hGH) and human leptin (hLeptin) as model

145 eric dynamics by conducting studies on human growth hormone (hGH) and pyrin domain (PYD), and the res

146 and tissue-specific activation of the human growth hormone (hGH) gene cluster in the pituitary and p

147 The human growth hormone (hGH) gene is controlled by a long-range

148 An indirect immunoassay format with human growth hormone (hGH) immobilized on the self-assembled m

149 Human growth hormone (hGH) is known to play a functional role

150 The human growth hormone (hGH) minigene used for transgene stabili

151 The human Growth Hormone (hGH) multigene cluster contains five gen

152 Recombinant human growth hormone (hGH) therapy in children with Prader-Wil

153 , we contrast IgG binding with that of human growth hormone (hGH) to its receptor (hGH-R) which displ

154 Ectopic human growth hormone (hGH) was highly expressed in MIP-CreERT

155 Human growth hormone (hGH), and its receptor interaction, is e

156 estigated the weak self-association of human growth hormone (hGH, KD = 0.90 +/- 0.03 mM) at neutral p

157 Human growth hormone (hGH-N) expression in the pituitary is un

158 The human pituitary growth hormone (hGH-N) locus is activated in the differe

159 These findings suggest that the growth hormone/IGF-I system may be a potential therapeut

160 Mechanistically, direct upregulation of the growth hormone IGF2 emerged as a mediator of the aggress

161 previously unrecognized role for ghrelin and growth hormone in maladaptive changes following prolonge

162 ke growth factor 2 (IGF2) is the major fetal growth hormone in mammals.

163 Auxin is a major growth hormone in plants, and recent studies have elucid

164 findings demonstrate the functional role of growth hormone in promoting thrombopoiesis and provide a

165 characterizing the interaction between human growth hormone in solution and the corresponding antibod

166 nitial step in the biosynthesis of the plant growth hormone indole-acetic acid by bacterial pathogens

167 Igf-1 transcription is regulated through growth hormone-induced, JAK2 kinase-mediated phosphoryla

168 In particular, the enzymes activated by growth hormone, insulin, and insulin-like growth factor-

169 which carry single-gene mutations within the growth-hormone, insulin/IGF-1 or mTOR signalling pathway

170 e mice promotes growth while suppressing the growth hormone-insulin-like growth factor-1 (GH-IGF-1) a

171 oduction and associates with abrogation of a growth hormone/insulin-like growth factor 1 (GH/IGF1) ax

172 The data suggest that an altered growth hormone/insulin-like growth factor 1 axis, which

173 As IGFBP3 plays a key role in regulating the growth hormone/insulin-like growth factor type 1 (GH/IGF

174 We identified dysregulation of the Growth Hormone/Insulin-like Growth Factor-1 (GH/IGF-1) p

175 Growth hormone is disrupted most often, followed by gona

176 Increased secretion of growth hormone leads to gigantism in children and acrome

177 Moreover, nitrate increased circulating growth hormone levels in humans and rodents.

178 crosis factor-alpha, cortisol, glucagon, and growth hormone levels increased, and free fatty acids an

179 Growth hormone levels were significantly higher in juven

180 Growth hormone levels were studied both in vivo and in v

181 ated insulin-like growth factor 1 levels and growth hormone levels; initial treatment is surgical.

182 as evidenced by increased plasma ghrelin and growth-hormone levels.

183 ith isolated growth hormone deficiency [peak growth hormone <6.7 microg/l (mean 3.5 microg/l)] and 14

184 study was to test whether fasting levels of growth hormone measured with a high-sensitivity assay (h

185 escent host liver repopulation involving the growth hormone-mediated release of the transcriptional b

186 nile than in senescent rats, suggesting that growth hormone might promote host liver repopulation.

187 hancing efficiency of CriticalSorb for human growth hormone (MW 22 kDa) was investigated in the consc

188 *05, DQB1*02, DQB1*03:02 alleles), and human growth hormone (positive control).

189 lease of growth hormone and proliferation of growth hormone-producing cells.

190 ne disease, and the use of recombinant human growth hormone provide some hope for catch-up growth in

191 a co-chaperone and regulator of androgen and growth hormone receptor (AR, GHR) signalling.

192 Growth hormone receptor (GHR) endocytosis is a highly re

193 To clarify the divergence of the growth hormone receptor (GHR) family, we characterized a

194 Growth hormone receptor (Ghr) signaling is important in

195 rtial hepatectomy by preventing increases in growth hormone receptor (GHR) via ubiquitination, suppre

196 re variation in Europeans and for genes with growth hormone receptor and regulation functions.

197 ul5-Rbx2 (CRL5(SOCS2)), binds phosphorylated growth hormone receptor as its main substrate.

198 .SIGNIFICANCE STATEMENT People and mice with growth hormone receptor deficiency (GHRD or Laron syndro

199 Growth hormone receptor deficiency (GHRD) results in sho

200 es using beads decorated with phosphorylated growth hormone receptor peptides.

201 The exon 3-deleted growth hormone receptor polymorphism (GHR(d3)) may accou

202 ased on an archetypal cytokine receptor, the growth hormone receptor.

203 ons, as well as sex-biased binding sites for growth hormone-regulated transcriptional activators (STA

204 including two rat lincRNAs showing the same growth hormone-regulated, sex-biased expression as their

205 for five transcription factors implicated in growth hormone-regulated, sex-biased liver gene expressi

206 states, transcription factor occupancy, and growth hormone regulation provides novel insights into t

207 This study aimed to investigate whether the growth hormone release and metabolic effects of ghrelin

208 uthorities due to their ability to stimulate growth hormone release from the pituitary.

209 sly revealed promising results in inhibiting growth hormone release in pituitary somatotrophs.

210 Interestingly, in vivo or in vitro growth hormone release is intact in response to ghrelin

211 GHSR1a enhances growth hormone release, appetite, and dopamine signaling

212 to circulation, affecting energy balance and growth hormone release.

213 l modification to stimulate both feeding and growth hormone release.

214 uteinizing hormone releasing hormone (LHRH), growth hormone releasing hexapeptide (GHRP-6), and TrpCa

215 elanocortin (POMC), neuropeptide Y (NPY) and growth hormone releasing hormone (GHRH) neurons, regulat

216 s LHn from serotype D with a fragment of the growth hormone releasing hormone, has previously reveale

217 The most promising candidates are the growth hormone releasing peptide (GHRP)-1, -2, -4, -5, -

218 Azapeptide analogues of growth hormone releasing peptide-6 (GHRP-6) exhibit prom

219 Pretreatment with the growth hormone-releasing hormone (GHRH) agonist, JI-36,

220 Because growth hormone-releasing hormone (GHRH) and GHRH recepto

221 ) deficiency with inadequate compensation by Growth hormone-releasing hormone (GHRH) and Growth hormo

222 therapeutic effects of agonistic analogs of growth hormone-releasing hormone (GHRH) and their mechan

223 Preclinical studies suggest that growth hormone-releasing hormone (GHRH) antagonists effe

224 eurons, and two growth-stimulatory peptides, growth hormone-releasing hormone (GHRH) for GHRH-neurons

225 Growth hormone-releasing hormone (GHRH) has been previou

226 Agonists of growth hormone-releasing hormone (GHRH) have been previo

227 examine the impact of targeted disruption of growth hormone-releasing hormone (GHRH) in mice on longe

228 Antagonists of hypothalamic growth hormone-releasing hormone (GHRH) inhibit growth o

229 Growth hormone-releasing hormone (GHRH) is a hypothalami

230 Hypothalamic growth hormone-releasing hormone (GHRH) neurons orchestr

231 It has been shown that growth hormone-releasing hormone (GHRH) reduces cardiomy

232 The hypothalamic growth hormone-releasing hormone (GHRH) regulates the re

233 ith corticotropin-releasing factor (CRF) and growth hormone-releasing hormone (GHRH), suggesting nove

234 In view of the multiple activities of growth hormone-releasing hormone (GHRH), we hypothesized

235 Tesamorelin, a growth hormone-releasing hormone analog, specifically ta

236 ic IGF-1 production resulted from diminished growth hormone-releasing hormone expression in the hypot

237 The beneficial effects of agonists of growth hormone-releasing hormone receptor (GHRH-R) in he

238 ine methyl ester (L-NAME) and stimulation of growth hormone-releasing hormone receptor (GHRHR) with G

239 re transplantation using a potent agonist of growth-hormone-releasing hormone (GHRH) to promote islet

240 ntrolled studies of the effects of long-term growth hormone replacement on fracture risk in adult pat

241 Our results suggest that growth hormone replacement therapy could be protective a

242 erting enzyme inhibitors, beta-blockers, and growth hormone replacement therapy.

243 es chronic systemic inflammation, leading to growth hormone resistance and impaired linear growth.

244 alamic amenorrhoea; a nutritionally acquired growth-hormone resistance leading to low concentrations

245 pmental maturation of hepatic IGF-1 intron 2 growth hormone response element (IN2GHRE) histone methyl

246 stal weak enhancer (IGF-1 5'-upstream region growth hormone response element; 5URGHRE) as a GHRE spec

247 lly regulated by growth hormone (GH) through growth hormone response elements (GHREs).

248 ine, norepinephrine, glucagon, cortisol, and growth hormone responses were similarly reduced after al

249 HIIT suppressed cortisol and growth hormone responses, but not catecholamine response

250 ine, norepinephrine, glucagon, cortisol, and growth hormone responses.

251 Benefits of recombinant human growth hormone (rhGH) alone or combined with glutamine i

252 for the quantification of recombinant human growth hormone (rhGH) in serum has been developed using

253 Recombinant human growth hormone (rhGH) reduces visceral adipose tissue (V

254 Recombinant human growth hormone (rhGH) therapy is used in the long-term t

255 enous hormones estrogen or recombinant human growth hormone (rhGH).

256 Somatropin (i.e., recombinant human growth hormone, rhGH) modified with the chelating agent

257 ained another unapproved drug, including the growth hormone secretagogue ibutamoren, the peroxisome p

258 The truncated non-signaling ghrelin receptor growth hormone secretagogue R1b (GHS-R1b) has been sugge

259 Ghrelin's effect is mediated by its receptor Growth Hormone Secretagogue Receptor (GHS-R), but the ph

260 Growth hormone secretagogue receptor (GHSR) 1a is the on

261 ding to the only known ghrelin receptor, the growth hormone secretagogue receptor (GHSR).

262 actions of ghrelin are mediated through the growth hormone secretagogue receptor 1a (ghrelin recepto

263 The ghrelin receptor, also known as the growth hormone secretagogue receptor 1a (GHS-R1a), is a

264 by the stomach and acts at its receptor, the growth hormone secretagogue receptor 1a (GHSR1a), in the

265 A novel neuronal growth hormone secretagogue receptor circuit involving u

266 ility by activating KATP conductance via the growth hormone secretagogue receptor subtype 1a-Galphai

267 tion of a postsynaptic ghrelin receptor, the growth hormone secretagogue receptor type 1a (GHS-R1a),

268 Ghrelin, the natural ligand of the growth hormone secretagogue receptor type 1a (GHS-R1a),

269 The growth hormone secretagogue receptor, GHSR1a, mediates t

270 anterior pituitary cells express significant growth hormone secretagogue receptor.

271 Growth hormone secretagogue receptors (GHSRs) in the cen

272 ly by the expression of the ghrelin receptor growth hormone secretagogue type 1a (GHS-R1a) in the hyp

273 ange of product variants in samples of human growth hormone secreted from Pichia pastoris.

274 Growth hormone-secreting tumors account for 8% to 16% of

275 ed receptor GHS-R1a mediates ghrelin-induced growth hormone secretion, food intake, and reward-seekin

276 number of physiological processes including growth hormone secretion, food intake, as well as energy

277 lin, an octanoylated peptide that stimulates growth hormone secretion.

278 tial for intracellular protein sorting, cell growth, hormone secretion, and neurotransmission.

279 /-) mice had increased activation of hepatic growth hormone-signal transducer and activator of transc

280 diposity in association with blunted hepatic growth hormone signaling.

281 ch is decoupled from direct glucose sensing, growth-hormone signalling and stem-cell maintenance.

282 ed on the responses of the liver lincRNAs to growth hormone stimulation, which imparts clinically rel

283 Short-term growth hormone substitution might improve liver repopula

284 ence rate was lower in patients who received growth hormone than in those who did not (fracture incid

285 We further showed using murine growth hormone that postnatal intervention with both the

286 Starting growth hormone therapy before the onset of osteoporosis

287 Recombinant human growth hormone therapy of children with idiopathic short

288 Deciding when to pursue recombinant human growth hormone therapy to increase adult height is contr

289 ntiepileptic drugs and the efficacy of human growth hormone therapy, and few data are available for t

290 y and the evaluation of the effectiveness of growth hormone therapy.

291 ptotic proteins PUMA and BIM were induced by growth hormone through STAT5, which bound to GAS motifs

292 Application of IGF-1 and growth hormone to human meibomian gland epithelial cells

293 of the structural and cognitive deficits on growth hormone treatment are now required to confirm tha

294 between patients who did and did not receive growth hormone treatment in the subgroup of patients wit

295 Growth hormone treatment may be considered in some child

296 We assessed the effect of growth hormone treatment on fracture risk in patients wi

297 The effect of growth hormone treatment on fracture risk was assessed b

298 ces might miss the opportunity for effective growth hormone treatment.

299 Cytokines and growth hormones typically activate STATs and could there

300 orionic somatomammotropin (CS) and placental growth hormone variant (GH-V) act as metabolic adaptors